Mylan N.V received FDA approval for Ermeza (levothyroxine), which is available in oral dose formulations such as generic tablet and capsule forms, and can be used as a supplemental treatment to surgery and radioiodine therapy or as a replacement therapy for congenital or acquired hypothyroidism in adult and pediatric patients.
Zydus Lifesciences got approval from the US Food and Drug Administration (USFDA) for marketing the Levothyroxine Sodium Injection which is used to treat myxedema coma or extreme hypothyroidism.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4897
Published Date: May 02, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Higher prevalence of type 1 diabetes and the growing geriatric population are the major factors driving the growth of the market.
The market size of myxedema coma is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023-2035.
The major players in the market are Merck & Co., Inc., Pfizer Inc., GSK plc., Sanofi Global, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Lannett Company, Inc., Zydus Lifesciences.
The oral segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
: The major players in the market are AbbVie Inc., Merck & Co., Inc., Pfizer Inc., GSK plc., and more.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.